Indian Colleges Are Introducing Cloud Computing Curriculum From AWS Educate

Cloud technology has advanced to the forefront as millions of people around the world are using computing technology to work remotely due to the outbreak of Covid-19. In the future, it will enable seamless pathways from classrooms to careers at all education levels. Seven higher-level educational institutions recently chose AWS as their choice of platform for this far-reaching approach to enhance students with cloud skills. 

With this, the institutions are aiming for a cloud curriculum from AWS Educate, which gives a practical learning experience for students much needed for today’s job market. Under the AWS Educate global initiative, the cloud giant has provided students and educators with the resources required to speed up cloud-related learning by designing college degree programs with cloud computing curriculum. 

The goal of the initiative is also to bring cloud computing to mainstream college syllabus and produce the next generation of cloud specialists in India. The cloud computing curriculum is going to be included as an undergraduate degree and postgraduate diploma programs commencing in computer engineering jobs. 

Veracyte's Prosigna IDs Breast Cancer Patients Likely to Benefit from Aggressive Chemotherapy

A new retrospective study published in NPJ Breast Cancer on Monday suggests that Veracyte's Prosigna breast cancer prognostic gene signature assay can identify the subgroups of patients who are more likely to benefit from aggressive chemotherapy.

Veracyte obtained exclusive global diagnostic rights to NanoString Technologies' nCounter FLEX Analysis System last December, and with it gained the rights to the Prosigna test.

what is nids -cleared prognostic gene signature assay is intended to be used to gauge the 10-year recurrence risk in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive breast cancer. The recurrence risk provided by the test can be useful information for physicians trying to decide how aggressively to treat patients with hormone therapy.

The NPJ Breast Cancer study analyzed data from the DBCG89D trial — a randomized trial of 980 pre- and post-menopausal Danish women with early-stage breast cancer who were administered adjuvant chemotherapy regimens containing the anthracycline epirubicin, or cyclophosphamide/methotrexate/fluorouracil (CMF). The Prosigna 50-gene assay was successfully performed on 686 patients, of whom 38 percent had a basal-like breast cancer subtype, 32 percent had HER2-enriched subtype, 19 percent had luminal A, and 11 percent had luminal B.

Among the non-HER2-enriched, patients, 38 were clinically HER2-positive and 30 were TOP2A abnormal. HER2-enriched is a subtype of HER2-positive breast cancer that's characterized by high expression of ERBB2 and related genes. The HER2-enriched biomarker has also been associated with a higher likelihood of achieving pathological complete response following neoadjuvant anti-HER2-based therapy beyond hormone receptor status and chemotherapy use.